Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma

Z. Apalla, A. Lallas, T. Tzellos, T. Sidiropoulos, I. Lefaki, M. Trakatelli, E. Sotiriou, E. Lazaridou, G. Evangelou, A. Patsatsi, A. Kyrgidis, A. Stratigos, I. Zalaudek, G. Argenziano, D. Ioannides

Research output: Contribution to journalArticle

Abstract

Background Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after nonablative therapies has not been sufficiently assessed. Objectives Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels, have been suggested to predict the presence of residual disease [residual disease-associated dermoscopic criteria (RDADC)]. We aimed to assess this hypothesis. Patients and methods Lesions exhibiting RDADC 3 months after treatment were biopsied and in the case of histopathological confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months. Results At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25·5%) sBCCs, in which histology confirmed tumour persistence. In 45 (61·6%) of the 73 remaining lesions, dermoscopy showed white/red structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17·8%) of the 73 lesions. Conclusions RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathological clearance. Detection of white/red structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence. What's already known about this topic? Nonablative therapeutic modalities are licensed for the management of superficial basal cell carcinomas (sBCC). Few data are available concerning utility of dermoscopy in the evaluation of sBCCs after nonablative therapies. What does this study add? The current study suggests the usefulness of dermoscopy in the assessment of treatment outcome and monitoring of sBCCs. Based on dermoscopy, physicians may avoid post-treatment diagnostic biopsies, or overtreatment, which increase patients' morbidity and therapeutic cost.

Original languageEnglish
Pages (from-to)809-815
Number of pages7
JournalBritish Journal of Dermatology
Volume170
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Dermoscopy
Basal Cell Carcinoma
Telangiectasis
Therapeutics
Histology
Morbidity
Physicians
Biopsy
Costs and Cost Analysis
Recurrence

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. / Apalla, Z.; Lallas, A.; Tzellos, T.; Sidiropoulos, T.; Lefaki, I.; Trakatelli, M.; Sotiriou, E.; Lazaridou, E.; Evangelou, G.; Patsatsi, A.; Kyrgidis, A.; Stratigos, A.; Zalaudek, I.; Argenziano, G.; Ioannides, D.

In: British Journal of Dermatology, Vol. 170, No. 4, 2014, p. 809-815.

Research output: Contribution to journalArticle

Apalla, Z, Lallas, A, Tzellos, T, Sidiropoulos, T, Lefaki, I, Trakatelli, M, Sotiriou, E, Lazaridou, E, Evangelou, G, Patsatsi, A, Kyrgidis, A, Stratigos, A, Zalaudek, I, Argenziano, G & Ioannides, D 2014, 'Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma', British Journal of Dermatology, vol. 170, no. 4, pp. 809-815. https://doi.org/10.1111/bjd.12749
Apalla, Z. ; Lallas, A. ; Tzellos, T. ; Sidiropoulos, T. ; Lefaki, I. ; Trakatelli, M. ; Sotiriou, E. ; Lazaridou, E. ; Evangelou, G. ; Patsatsi, A. ; Kyrgidis, A. ; Stratigos, A. ; Zalaudek, I. ; Argenziano, G. ; Ioannides, D. / Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. In: British Journal of Dermatology. 2014 ; Vol. 170, No. 4. pp. 809-815.
@article{38ea80ec47a4441789183411481b36dc,
title = "Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma",
abstract = "Background Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after nonablative therapies has not been sufficiently assessed. Objectives Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels, have been suggested to predict the presence of residual disease [residual disease-associated dermoscopic criteria (RDADC)]. We aimed to assess this hypothesis. Patients and methods Lesions exhibiting RDADC 3 months after treatment were biopsied and in the case of histopathological confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months. Results At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25·5{\%}) sBCCs, in which histology confirmed tumour persistence. In 45 (61·6{\%}) of the 73 remaining lesions, dermoscopy showed white/red structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17·8{\%}) of the 73 lesions. Conclusions RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathological clearance. Detection of white/red structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence. What's already known about this topic? Nonablative therapeutic modalities are licensed for the management of superficial basal cell carcinomas (sBCC). Few data are available concerning utility of dermoscopy in the evaluation of sBCCs after nonablative therapies. What does this study add? The current study suggests the usefulness of dermoscopy in the assessment of treatment outcome and monitoring of sBCCs. Based on dermoscopy, physicians may avoid post-treatment diagnostic biopsies, or overtreatment, which increase patients' morbidity and therapeutic cost.",
author = "Z. Apalla and A. Lallas and T. Tzellos and T. Sidiropoulos and I. Lefaki and M. Trakatelli and E. Sotiriou and E. Lazaridou and G. Evangelou and A. Patsatsi and A. Kyrgidis and A. Stratigos and I. Zalaudek and G. Argenziano and D. Ioannides",
year = "2014",
doi = "10.1111/bjd.12749",
language = "English",
volume = "170",
pages = "809--815",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma

AU - Apalla, Z.

AU - Lallas, A.

AU - Tzellos, T.

AU - Sidiropoulos, T.

AU - Lefaki, I.

AU - Trakatelli, M.

AU - Sotiriou, E.

AU - Lazaridou, E.

AU - Evangelou, G.

AU - Patsatsi, A.

AU - Kyrgidis, A.

AU - Stratigos, A.

AU - Zalaudek, I.

AU - Argenziano, G.

AU - Ioannides, D.

PY - 2014

Y1 - 2014

N2 - Background Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after nonablative therapies has not been sufficiently assessed. Objectives Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels, have been suggested to predict the presence of residual disease [residual disease-associated dermoscopic criteria (RDADC)]. We aimed to assess this hypothesis. Patients and methods Lesions exhibiting RDADC 3 months after treatment were biopsied and in the case of histopathological confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months. Results At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25·5%) sBCCs, in which histology confirmed tumour persistence. In 45 (61·6%) of the 73 remaining lesions, dermoscopy showed white/red structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17·8%) of the 73 lesions. Conclusions RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathological clearance. Detection of white/red structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence. What's already known about this topic? Nonablative therapeutic modalities are licensed for the management of superficial basal cell carcinomas (sBCC). Few data are available concerning utility of dermoscopy in the evaluation of sBCCs after nonablative therapies. What does this study add? The current study suggests the usefulness of dermoscopy in the assessment of treatment outcome and monitoring of sBCCs. Based on dermoscopy, physicians may avoid post-treatment diagnostic biopsies, or overtreatment, which increase patients' morbidity and therapeutic cost.

AB - Background Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after nonablative therapies has not been sufficiently assessed. Objectives Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels, have been suggested to predict the presence of residual disease [residual disease-associated dermoscopic criteria (RDADC)]. We aimed to assess this hypothesis. Patients and methods Lesions exhibiting RDADC 3 months after treatment were biopsied and in the case of histopathological confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months. Results At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25·5%) sBCCs, in which histology confirmed tumour persistence. In 45 (61·6%) of the 73 remaining lesions, dermoscopy showed white/red structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17·8%) of the 73 lesions. Conclusions RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathological clearance. Detection of white/red structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence. What's already known about this topic? Nonablative therapeutic modalities are licensed for the management of superficial basal cell carcinomas (sBCC). Few data are available concerning utility of dermoscopy in the evaluation of sBCCs after nonablative therapies. What does this study add? The current study suggests the usefulness of dermoscopy in the assessment of treatment outcome and monitoring of sBCCs. Based on dermoscopy, physicians may avoid post-treatment diagnostic biopsies, or overtreatment, which increase patients' morbidity and therapeutic cost.

UR - http://www.scopus.com/inward/record.url?scp=84929940961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929940961&partnerID=8YFLogxK

U2 - 10.1111/bjd.12749

DO - 10.1111/bjd.12749

M3 - Article

C2 - 24283541

AN - SCOPUS:84929940961

VL - 170

SP - 809

EP - 815

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 4

ER -